Evaluation of plasma anti-CS3 and anti-LTB IgG avidity among Zambian children vaccinated with ETVAX
PLOS One · 15.05.2026 · 21 (5) · e0335327
DOI: 10.1371/journal.pone.0335327 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 15.05.2026. Verfasst von Cynthia Mubanga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Basic science and immunology Department, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. Hauptthemen laut MEDLINE: Enterotoxigenic Escherichia coli, Escherichia coli Infections, Escherichia coli Vaccines. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Enterotoxigenic Escherichia coli (ETEC) remains a major cause of diarrheal disease in low- and middle-income countries (LMICs). To curb ETEC related diarrhoea, several candidate vaccines are in development, with ETVAX® being the most advanced. Although immunogenicity studies have primarily focused on measuring antibody titres, assessing antibody avidity offers additional valuable insight into antibody quality and immune maturity. This study assessed anti-CS3 and anti-LTB IgG avidity in Zambian children to better understand vaccine-induced antibody responses in an endemic setting.
Methods
Children aged 6–23 months (n = 60) received three quarter-doses of ETVAX® with dmLT adjuvant on days 1, 14, and 90. Plasma samples collected at baseline prior to the first vaccination (Day 1; V1), seven days after the second dose (Day 22; V5), and seven days after the third dose (Day 97; V7) were analysed by limiting antigen dilution ELISA to calculate avidity indices (AI). Naïve classification was performed using titre-based thresholds (20th percentile of baseline titres) and avidity-defined naivety (AI < 0.5). Receiver operating characteristic (ROC) analysis was used to evaluate the discriminatory performance of avidity indices against titre-defined naïve status.
Results
Baseline avidity was detectable for both CS3 and LTB, consistent with prior natural exposure. Mean CS3 IgG avidity decreased from 0.7 at baseline to 0.6 after the third dose ( p < 0.001), while LTB IgG avidity showed transient decreases but no net gain. Naïve classification at baseline revealed that 9/60 children had titres but low avidity (functional naivety), and 6/60 had waned titres but high avidity. Only one child was naïve by both criteria for CS3, and none for LTB. ROC analysis demonstrated moderate discrimination for CS3 (AUC = 0.65; optimal cut-off AI = 0.36) but poor discrimination for LTB (AUC = 0.30).
Conclusion
In this endemic population, ETVAX® induced strong antibody titres but minimal changes in avidity over time, with notable inter-individual variability. ROC analysis highlighted context-specific limitations in using avidity to discriminate immune maturity. Together, these findings suggest that while antibody avidity may provide complementary information on antibody quality, its interpretation should be cautious and considered alongside antibody titres in endemic settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Basic science and immunology Department, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
- Division of Medical Microbiology & Immunology, Department of Pathology, Stellenbosch University & National Health Laboratory Service, Tygerberg Hospital Francie van Zijl Drive, Tygerberg, Cape Town, South Africa.
- Laboratory Servies Department, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
- Research Department, Maryland Global Initiatives Corporation (MGIC), Kabulonga, Lusaka, Zambia.
- Department of Pathology and Microbiology, University of Zambia, School of Medicine, Lusaka, Zambia.
- Zambia National Public Health Institute, Corner of Chaholi & Addis Ababa Roads,Rhoadespark, Lusaka, Zambia.
ORCID-Profile: Cynthia Mubanga, Obvious Nchimunya Chilyabanyama, Caroline C Chisenga
Zitieren
APA
Mubanga, C., Mubanga, M., Chilyabanyama, O. N., Phiri, M., Chisenga, C. C., Glashoff, R. H., & Chilengi, R. (2026). Evaluation of plasma anti-CS3 and anti-LTB IgG avidity among Zambian children vaccinated with ETVAX. PLOS One, 21(5), e0335327. https://doi.org/10.1371/journal.pone.0335327
Vancouver
Mubanga C, Mubanga M, Chilyabanyama ON, Phiri M, Chisenga CC, Glashoff RH, et al. Evaluation of plasma anti-CS3 and anti-LTB IgG avidity among Zambian children vaccinated with ETVAX. PLOS One. 2026;21(5):e0335327. doi:10.1371/journal.pone.0335327
BibTeX
@article{Mubanga2026,
author = {Mubanga, Cynthia and Mubanga, Mutale and Chilyabanyama, Obvious Nchimunya and Phiri, Masauso and Chisenga, Caroline C and Glashoff, Richard H and Chilengi, Roma},
title = {Evaluation of plasma anti-CS3 and anti-LTB IgG avidity among Zambian children vaccinated with ETVAX},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0335327},
doi = {10.1371/journal.pone.0335327}
}
EUVIMED